Conclusions
Based on our findings, our study is the first time to describe the novel function of PDIA4 and we propose a new linkage between PDIA4 and various immune components in glioma. PDIA4 is highly expressed in glioma and significantly related with the clinical outcomes. The tumor promoting character of PDIA4 is potentially mediated by the immune system because of the certain connections with multiple immune factors in the glioma TME. The detailed molecular mechanism of PDIA4 and the development of glioma need to be further illustrated. To this end, our study provides novel possibilities for future discoveries to find new therapeutic approaches by targeting PDIA4 for immunotherapy in glioma.